Meeting
2019 Genitourinary Cancers Symposium
Tobacco as a possible prognostic factor in advanced renal cell carcinoma.
Authors
Maria Pilar Solis-Hernandez
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
Maria Pilar Solis-Hernandez , Clara Iglesias , Alfonso Revuelta , Carmen Gonzalez Mendez , Lucia Juan Rodriguez , Teresa Quiñones Roces , Sara Gonzalez Lolo , Jorge del Río Fernández , David Gómez , Sena Valcárcel González , Sara Fernandez Arrojo , Carlos Alvarez-Fernandez , Noemí Villanueva , Laura Faez , Esther Uriol Sr., Emilio Esteban
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 665)
DOI
10.1200/JCO.2019.37.7_suppl.665
Abstract #
665
Poster Bd #
J18
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).
First Author: Giuseppe Procopio
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
First Author: Ana-Alicia Beltran-Bless
Poster
2024 ASCO Genitourinary Cancers Symposium
Lenvatinib plus everolimus (LenEve) in patients with pre-treated advanced renal cell carcinoma (mRCC): Real world evidence (Relevance).
First Author: Philipp Ivanyi
Poster
2024 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
First Author: Viktor Grünwald